Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines

TL;DR

This narrative review synthesizes clinical, mechanistic, and guideline evidence on plant-derived treatments for IBS. Peppermint oil is the most consistently effective and the only plant-based therapy broadly recommended across international adult and pediatric guidelines, while Iberogast, curcumin, and some TCM/Kampo formulations show more limited or region-specific evidence and several other extracts lack demonstrated efficacy.

Key findings

• Peppermint oil was the most studied and effective botanical agent, with meta-analyses finding it safe and superior to placebo for abdominal pain and global IBS symptoms. Trials reported improvements at 4 weeks (p < 0.009), 8 weeks (p < 0.001), and in a 190-patient trial for abdominal pain (p = 0.016), abdominal discomfort (p = 0.020), and IBS symptom severity (p = 0.020), though overall symptom relief was not significant (p = 0.170); a phase 3 trial in 69 Japanese patients showed significant improvements in symptom severity, stool frequency, patient global assessment, and stool form. Guidelines consistently acknowledge peppermint oil, with ACG conditional/low-quality, BSG weak/very-low-quality, Polish strong/moderate-quality, and JSGE weak/high-quality recommendations for adjunctive use.
• Iberogast (STW 5 and STW 5-II) showed clinical improvements: a 10-patient IBS bloating study found improved colonic gas tolerance (p = 0.035) and reduced gas-related symptoms (p = 0.016); a 418-pediatric-patient observational study reported GIS improvement (p < 0.0001) with 0.7% adverse events; and a 2004 multicenter RCT (n = 51 STW 5, n = 52 STW 5-II, n = 52 placebo) modestly reduced abdominal pain (p = 0.0009 and p = 0.0005) and IBS symptom scores (p = 0.001 and p = 0.0003). Mexican and German guidelines mention STW-5 with low-quality evidence, while the Saudi CHI concluded insufficient evidence.
• Curcumin/turmeric showed mechanistic and preliminary clinical potential, with a meta-analysis of 551 adults reporting improved quality of life and reduced IBS-SSS and abdominal pain, though many included studies had methodological limitations. TCM trials reported benefit: JCM-16021 in two multicenter RCTs of 392 participants alleviated IBS-D abdominal pain; Tong-Xie-Yao-Fang in 160 adults was more effective than placebo for IBS-D; and XSLJZT in 80 IBS patients improved GI symptoms and quality of life in IBS-D. Kampo is recommended by the Japanese Society of Gastroenterology and the Second Asian Consensus but has not been studied in Western populations.
• Several extracts showed controversial or no efficacy: soy flavonoids in 67 IBS patients reduced IBS-QoL (p = 0.009) but not IBS-SSS (p = 0.068); Aloe vera meta-analysis of 151 patients found improvement (SMD 0.41; 95% CI 0.07–0.75; p = 0.020), but another meta-analysis of 3 RCTs found no improvement (p = 0.12, p = 0.09, p > 0.05); St John’s wort reduced symptoms in 20 women (p < 0.01) but a 12-week trial showed lower efficacy than placebo (p = 0.03); ginger alone in 45 IBS patients showed no significant improvement (p > 0.05); Curcuma xanthorriza pain increased versus placebo (p = 0.81); Fumaria officinalis abdominal distension increased in the treatment group (p = 0.48); and an Ayurvedic compound showed no greater improvement than placebo in IBS-D.

Methods

• Narrative review aiming to summarize, compare, and critically evaluate all plant extracts studied for IBS prevention and management, integrating mechanistic pathways, clinical evidence, and international guideline recommendations.
• Evidence base included clinical trials, systematic reviews and meta-analyses, preclinical studies, and international guidelines from ACG, CAG, Mexican, BSG, UEG/ESNM, DGVS/DGNM, Polish, Asian, JSGE, Korean, Saudi CHI, and ESPGHAN/NASPGHAN.
• Main analysis was a narrative synthesis of selected trial outcomes, mechanistic findings, and guideline recommendations; no systematic search strategy, eligibility criteria, or formal risk-of-bias assessment is described in the text.

Limitations

• Stated: significant heterogeneity among herbal preparations—plant species, extraction techniques, standardization, and dosing regimens—limits direct comparisons across studies.
• Stated: quality of evidence for many extracts remains low due to small sample sizes, short study durations, or methodological problems; much mechanistic evidence derives from preclinical models that may not fully explain human IBS.
• Evident from the text: as a narrative review, it lacks a described systematic search, formal risk-of-bias assessment, or quantitative synthesis; guideline comparisons are limited by differing grading systems, with some recommendations not using GRADE. The text also notes that sex-stratified efficacy results were not reported across peppermint oil studies and that pediatric populations remain understudied.